Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ADIAL PHARMACEUTICALS, INC. entered into Placement Agency Agreement with Joseph Gunnar & Co., LLC (effective 2023-02-23).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Joseph Gunnar & Co., LLC
- Effective
- 2023-02-23
Exact text from the filing
The Registered Offering was also conducted pursuant to a placement agency agreement, dated February 23, 2023 (the “Placement Agency Agreement”), by and between the Company and Joseph Gunnar & Co., LLC (the “Placement Agent”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ADIAL PHARMACEUTICALS, INC. entered into Voting Agreement with the Investor (effective 2023-02-23).
- Action
- entry
- Counterparty
- the Investor
- Effective
- 2023-02-23
Exact text from the filing
The Company also entered into a voting agreement (the “Voting Agreement”) with the Investor, pursuant to which the Investor agrees to vote all shares of Common Stock that it beneficially owns on and after February 23, 2023 with respect to all of the proposals presented by the Company to the stockholders of the Company at the Company’s next meeting of its stockholders, including at every adjournment or postponement thereof, or any subsequent meeting of its stockholders duly called for the same or similar purposes.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ADIAL PHARMACEUTICALS, INC. entered into Purchase Agreement with an accredited institutional investor valued at approximately $750,000 (effective 2023-02-23).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an accredited institutional investor
- Value
- approximately $750,000
- Effective
- 2023-02-23
Exact text from the filing
entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited institutional investor (the “Investor”) providing for the issuance of 1,829,269 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”). Pursuant to the Purchase Agreement, the Investor is purchasing the Shares for an aggregate purchase price of approximately $750,000.
View on SEC.gov